A detailed history of Susquehanna International Group, LLP transactions in Biogen Inc. stock. As of the latest transaction made, Susquehanna International Group, LLP holds 261,147 shares of BIIB stock, worth $38.9 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
261,147
Previous 118,223 120.89%
Holding current value
$38.9 Million
Previous $27.4 Million 84.7%
% of portfolio
0.01%
Previous 0.01%

Shares

28 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$189.07 - $236.8 $27 Million - $33.8 Million
142,924 Added 120.89%
261,147 $50.6 Million
Q2 2024

Aug 15, 2024

SELL
$190.52 - $236.72 $23.9 Million - $29.6 Million
-125,191 Reduced 51.43%
118,223 $27.4 Million
Q1 2024

May 07, 2024

BUY
$212.02 - $267.71 $34.9 Million - $44.1 Million
164,824 Added 209.73%
243,414 $52.5 Million
Q4 2023

Feb 14, 2024

SELL
$222.59 - $267.94 $7.45 Million - $8.97 Million
-33,487 Reduced 29.88%
78,590 $20.3 Million
Q3 2023

Nov 14, 2023

BUY
$253.3 - $285.89 $18.6 Million - $21 Million
73,296 Added 189.0%
112,077 $28.8 Million
Q2 2023

Aug 11, 2023

SELL
$275.25 - $318.06 $14.1 Million - $16.3 Million
-51,337 Reduced 56.97%
38,781 $11 Million
Q1 2023

May 16, 2023

SELL
$256.56 - $292.34 $32.5 Million - $37 Million
-126,619 Reduced 58.42%
90,118 $25.1 Million
Q4 2022

Feb 14, 2023

BUY
$252.44 - $306.72 $12.7 Million - $15.5 Million
50,500 Added 30.38%
216,737 $60 Million
Q3 2022

Nov 14, 2022

BUY
$194.69 - $268.46 $12.4 Million - $17 Million
63,502 Added 61.81%
166,237 $44.4 Million
Q2 2022

Aug 15, 2022

SELL
$187.54 - $223.02 $31.4 Million - $37.4 Million
-167,627 Reduced 62.0%
102,735 $21 Million
Q1 2022

May 16, 2022

SELL
$193.77 - $244.14 $27.3 Million - $34.4 Million
-140,807 Reduced 34.25%
270,362 $56.9 Million
Q4 2021

Feb 14, 2022

BUY
$223.92 - $287.77 $4.5 Million - $5.79 Million
20,103 Added 5.14%
411,169 $98.6 Million
Q3 2021

Nov 15, 2021

BUY
$282.99 - $369.05 $3.89 Million - $5.08 Million
13,756 Added 3.65%
391,066 $111 Million
Q2 2021

Aug 11, 2021

BUY
$259.0 - $414.71 $30.2 Million - $48.4 Million
116,668 Added 44.76%
377,310 $131 Million
Q1 2021

May 17, 2021

SELL
$242.95 - $284.63 $101 Million - $119 Million
-417,254 Reduced 61.55%
260,642 $72.9 Million
Q4 2020

Feb 16, 2021

BUY
$236.26 - $355.63 $67.6 Million - $102 Million
286,040 Added 73.0%
677,896 $166 Million
Q3 2020

Nov 16, 2020

SELL
$264.77 - $305.71 $1.73 Million - $2 Million
-6,544 Reduced 1.64%
391,856 $111 Million
Q2 2020

Aug 14, 2020

BUY
$258.66 - $342.55 $62.1 Million - $82.3 Million
240,135 Added 151.73%
398,400 $107 Million
Q1 2020

May 15, 2020

SELL
$268.85 - $341.04 $16.8 Million - $21.3 Million
-62,521 Reduced 28.32%
158,265 $50.1 Million
Q4 2019

Feb 14, 2020

SELL
$220.06 - $304.07 $34.5 Million - $47.7 Million
-156,910 Reduced 41.54%
220,786 $65.5 Million
Q3 2019

Nov 14, 2019

BUY
$217.44 - $243.88 $8.83 Million - $9.91 Million
40,618 Added 12.05%
377,696 $87.9 Million
Q2 2019

Aug 16, 2019

BUY
$219.29 - $241.72 $4.11 Million - $4.53 Million
18,739 Added 5.89%
337,078 $78.8 Million
Q2 2019

Aug 14, 2019

SELL
$219.29 - $241.72 $65.3 Million - $71.9 Million
-297,559 Reduced 48.31%
318,339 $74.5 Million
Q1 2019

May 15, 2019

BUY
$216.71 - $338.96 $133 Million - $208 Million
614,098 Added 34116.56%
615,898 $146 Million
Q4 2018

Feb 14, 2019

SELL
$278.5 - $352.75 $1.8 Million - $2.28 Million
-6,456 Reduced 78.2%
1,800 $542,000
Q2 2018

Aug 14, 2018

SELL
$257.52 - $306.91 $2.23 Million - $2.66 Million
-8,651 Reduced 51.17%
8,256 $2.4 Million
Q1 2018

May 15, 2018

BUY
$260.13 - $367.91 $1.1 Million - $1.56 Million
4,242 Added 33.49%
16,907 $4.63 Million
Q4 2017

Feb 14, 2018

BUY
$307.64 - $344.58 $3.9 Million - $4.36 Million
12,665
12,665 $4.03 Million

Others Institutions Holding BIIB

About BIOGEN INC.


  • Ticker BIIB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 144,000,992
  • Market Cap $21.5B
  • Description
  • Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...
More about BIIB
Track This Portfolio

Track Susquehanna International Group, LLP Portfolio

Follow Susquehanna International Group, LLP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Susquehanna International Group, LLP with notifications on news.